CNS Drugs

, Volume 18, Issue 8, pp 485–504

Pharmacotherapy of Alcohol Dependence

A Review of the Clinical Data
  • Karl Mann
Review Article

Abstract

Over the last 20 years, the role of adjuvant pharmacotherapy in optimising outcome in rehabilitation programmes for alcohol-dependent patients has become increasingly evident. New avenues for rational drug treatment have arisen from better understanding of the neurobiological substrates of alcohol dependence, including adaptive changes in amino acid neurotransmitter systems, stimulation of dopamine and opioid peptide systems, and, possibly, changes in serotonergic activity.

Disulfiram, naltrexone and acamprosate are currently the only treatments approved for the management of alcohol dependence. However, there is still no unequivocal evidence from randomised controlled clinical trials that disulfiram improves abstinence rates over the long term. Aversive therapy with disulfiram is not without risk for certain patients, and should be closely supervised. Both naltrexone and acamprosate improve outcome in rehabilitation of alcohol-dependent patients, but seem to act on different aspects of drinking pathology. Naltrexone is thought to decrease relapse to heavy drinking by attenuating the rewarding effects of alcohol. However, data from the naltrexone clinical trial programme are somewhat inconsistent, with several large studies being negative. Acamprosate is believed to maintain abstinence by blocking the negative craving that alcohol-dependent patients experience in the absence of alcohol. The clinical development programme has involved a large number of patients and studies, of which the vast majority have shown a beneficial effect of acamprosate on increasing abstinence rates. Both drugs are generally well tolerated; nausea is reported by around 10% of patients treated with naltrexone, while the most frequent adverse effect reported with acamprosate is diarrhoea.

Another opioid receptor antagonist, nalmefene, has shown promising activity in pilot studies, and may have a similar profile to naltrexone. Data from studies of SSRIs in alcohol dependence are somewhat heterogeneous, but it appears that these drugs may indirectly improve outcome by treating underlying depression rather than affecting drinking behaviour per se. Similarly, the anxiolytic buspirone may act by ameliorating underlying psychiatric pathology. Dopaminergic neuroleptics, benzodiazepines and antimanic drugs have not yet demonstrated evidence of activity in large controlled clinical trials. Trials with drugs acting at serotonin receptors have yielded disappointing results, with the possible exception of ondansetron.

Because the biological basis of alcohol dependence appears to be multifactorial, the future of management of alcoholism may be combination therapy, using drugs acting on different neuronal pathways, such as acamprosate and naltrexone. Pharmacotherapy should be used in association with appropriate psychosocial support and specific treatment provided for any underlying psychiatric comorbidities.

References

  1. 1.
    Maisto SA, Connors GJ, Zywiak WH. Alcohol treatment, changes in coping skills, self-efficacy, and levels of alcohol use and related problems 1 year following treatment initiation. Psychol Addict Behav 2000; 14: 257–66PubMedGoogle Scholar
  2. 2.
    Faingold CL, N’gouemo P, Riaz A. Ethanol and neurotransmitter interactions: from molecular to integrative effects. Prog Neurobiol 1998; 55: 509–35PubMedGoogle Scholar
  3. 3.
    Koob GF, Roberts AJ, Schulteis G, et al. Neurocircuitry targets in ethanol reward and dependence. Alcohol Clin Exp Res 1998; 22: 3–9PubMedGoogle Scholar
  4. 4.
    Spanagel R, Zieglgänsberger W. Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. Trends Pharmacol Sci 1997; 18: 37–65Google Scholar
  5. 5.
    Samson HH, Harris RA. The neurobiology of alcohol abuse. Trends Pharmacol Sci 1992; 13: 206–11PubMedGoogle Scholar
  6. 6.
    Grobin AC, Matthews DB, Devaud LL, et al. The role of GABAA receptors in the acute and chronic effects of ethanol. Psychopharmacology 1998; 139: 2–19PubMedGoogle Scholar
  7. 7.
    Olds ME, Fobes JL. The central basis of motivation: intracranial self-stimulation studies. Annu Rev Psychol 1981; 32: 523–74PubMedGoogle Scholar
  8. 8.
    Gessa GL, Muntoni F, Collu M, et al. Low doses of ethanol activate dopaminergic neurons in the ventral tegemental area. Brain Res 1985; 348: 201–3PubMedGoogle Scholar
  9. 9.
    Benjamin D, Grant E, Pohorecky LA. Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake, freely moving rats. Brain Res 1993; 621: 137–40PubMedGoogle Scholar
  10. 10.
    Gianoulakis C. Implications of endogenous opioids and dopamine in alcoholism: human and basic science studies. Alcohol Alcohol 1996; 31Suppl. 1: 33–42PubMedGoogle Scholar
  11. 11.
    Cardoso RA, Brozowski SJ, Chavez-Noriega LE, et al. Effects of ethanol on recombinant human neuronal nicotinic acetyl-choline receptors expressed in Xenopus oocytes. J Pharmacol Exp Ther 1999; 289: 774–80PubMedGoogle Scholar
  12. 12.
    Söderpalm B, Ericson M, Olausson P, et al. Nicotinic mechanisms involved in the dopamine activating and reinforcing properties of ethanol. Behav Brain Res 2000; 113: 85–96PubMedGoogle Scholar
  13. 13.
    Arendt F. Impairment in memory function and neurodegenerative changes in the cholinergic forebrain system induced by chronic intake of ethanol. J Neural Transm 1994; 44: 173–87Google Scholar
  14. 14.
    Sellers EM, Higgins GA, Sobell MB. 5-HT and alcohol abuse. Trends Pharmacol Sci 1992; 13: 69–75PubMedGoogle Scholar
  15. 15.
    Soubrié P. Reconciling the role of central serotonin neurons in human and animal behavior. Behav Brain Sci 1986; 9: 319–64Google Scholar
  16. 16.
    Modell JG, Glaser FB, Cyr L, et al. Obsessive and compulsive characteristics of craving for alcohol in alcohol abuse and dependence. Alcohol Clin Exp Res 1992; 16: 272–4PubMedGoogle Scholar
  17. 17.
    Anton RF, Moak DH, Latham P. The obsessive compulsive drinking scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behaviour. Alcohol Clin Exp Res 1995; 19: 92–9PubMedGoogle Scholar
  18. 18.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd rev. ed. (DSM-IV). Washington, DC: American Psychiatric Association, 1994Google Scholar
  19. 19.
    Lehert P. Review and discussion of statistical analysis of controlled clinical trials in alcoholism. Alcohol Alcohol Suppl 1993; 2: 157–63Google Scholar
  20. 20.
    Mundle G, Ackermann K, Munkes J, et al. Influence of age, alcohol consumption and abstinence on the sensitivity of carbohydrate-deficient transferrin, gamma-glutamyltransferase and mean corpuscular volume. Alcohol Alcohol 1999; 34: 760–6PubMedGoogle Scholar
  21. 21.
    Garbutt JC, West SL, Carey TS, et al. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA 1999; 281: 1318–25PubMedGoogle Scholar
  22. 22.
    Fuller RK, Branchey L, Brightwell DR, et al. Disulfiram treatment of alcoholism: a Veterans Administration cooperative study. JAMA 1986; 256: 1449–55PubMedGoogle Scholar
  23. 23.
    O’Malley SS, Jaffe AJ, Chang G, et al. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry 1992; 49: 881–7PubMedGoogle Scholar
  24. 24.
    Volpicelli JR, Alterman AI, Hayashida M, et al. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49: 876–80PubMedGoogle Scholar
  25. 25.
    Krystal JH, Cramer JA, Krol WF, et al. Naltrexone in the treatment of alcohol dependence. N Engl J Med 2001; 345: 1734–9PubMedGoogle Scholar
  26. 26.
    Hersh D, Van Kirk JR, Kranzler HR. Naltrexone treatment of comorbid alcohol and cocaine use disorders. Psychopharmacology 1998; 139: 44–52PubMedGoogle Scholar
  27. 27.
    Gastpar M, Bonnet U, Boning J, et al. Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. J Clin Psychopharmacol 2002; 22: 592–8PubMedGoogle Scholar
  28. 28.
    Guardia J, Caso C, Arias F, et al. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial. Alcohol Clin Exp Res 2002; 26: 1381–7PubMedGoogle Scholar
  29. 29.
    Kranzler HR, Modesto-Lowe V, Van Kirk JR. Naltrexone vs nefazodone for treatment of alcohol dependence: a placebo-controlled trial. Neuropsychopharmacology 2000; 22: 493–503PubMedGoogle Scholar
  30. 30.
    Chick J, Anton R, Checinski K, et al. A multicentre, randomised, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence in adults. Alcohol Alcohol 2000; 35: 587–93PubMedGoogle Scholar
  31. 31.
    Anton RF, Moak DH, Waid R, et al. Naltrexone and cognitive behavioral therapy of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry 1999; 156: 1758–64PubMedGoogle Scholar
  32. 32.
    Heinälä P, Alho H, Kiianmaa K, et al. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J Clin Psychopharmacol 2001; 21: 287–92PubMedGoogle Scholar
  33. 33.
    Balldin J, Berglund M, Borg S, et al. A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol Clin Exp Res 2003; 27: 1142–9PubMedGoogle Scholar
  34. 34.
    Monti PM, Rohsenow DJ, Hutchison KE, et al. Naltrexone’s effect on cue-elicited craving among alcoholics in treatment. Alcohol Clin Exp Res 1999; 23: 1386–94PubMedGoogle Scholar
  35. 35.
    Morris PL, Hopwood M, Whelan G, et al. Naltrexone for alcohol dependence: a randomized controlled trial. Addiction 2001; 96: 1565–73PubMedGoogle Scholar
  36. 36.
    Latt NC, Jurd S, Houseman J, et al. Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting. Med J Aust 2002; 176: 530–4PubMedGoogle Scholar
  37. 37.
    Volpicelli JR, Rhines KC, Rhines JS, et al. Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry 1997; 54: 737–42PubMedGoogle Scholar
  38. 38.
    Oslin D, Liberto JG, O’Brien J, et al. Naltrexone as an adjunctive treatment for older patients with alcohol dependence. Am J Geriatr Psychiatry 1997; 5: 324–32PubMedGoogle Scholar
  39. 39.
    Kranzler HR, Modesto-Lowe V, Nuwayser ES. Sustained-release naltrexone for alcoholism treatment: a preliminary study. Alcohol Clin Exp Res 1998; 22: 1074–9PubMedGoogle Scholar
  40. 40.
    Kiefer F, Jahn H, Tarnaske T, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2003; 60: 92–9PubMedGoogle Scholar
  41. 41.
    McCaul ME, Wand GS, Eissenberg T, et al. Naltrexone alters subjective responses to alcohol in heavy drinking subjects. Neuropsychopharmacology 2000; 22: 480–92PubMedGoogle Scholar
  42. 42.
    Monti PM, Rohsenow DJ, Swift RM, et al. Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcohol Clin Exp Res 2001; 25: 1634–47PubMedGoogle Scholar
  43. 43.
    Rohsenow DJ, Colby SM, Monti PM, et al. Predictors of compliance with naltrexone among alcoholics. Alcohol Clin Exp Res 2000; 24: 1542–9PubMedGoogle Scholar
  44. 44.
    Sinclair JD. Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism. Alcohol Alcohol 2001; 36: 2–10PubMedGoogle Scholar
  45. 45.
    Streeton C, Whelan G. Naltrexone, a relapse-prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcohol 2001; 36: 544–52PubMedGoogle Scholar
  46. 46.
    Kranzler HR, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 2001; 25: 1335–41PubMedGoogle Scholar
  47. 47.
    Srisurapanont M, Jarusuraisin N. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2000; (3): CD001867Google Scholar
  48. 48.
    O’Malley SS, Jaffe AJ, Chang G, et al. Six-month follow-up of naltrexone and psychotherapy for alcohol dependence. Arch Gen Psychiatry 1996; 53: 217–24PubMedGoogle Scholar
  49. 49.
    Anton RF, Moak DH, Latham PK, et al. Posttreatment results of combining naltrexone and cognitive behavior therapy for the treatment of alcoholism. J Clin Psychopharmacol 2001; 21: 72–7PubMedGoogle Scholar
  50. 50.
    Dahchour A, De Witte P. Ethanol and amino acids in the central nervous system: assessment of the pharmacological actions of acamprosate. Prog Neurobiol 2000; 60: 343–62PubMedGoogle Scholar
  51. 51.
    Johnson BA, Ait-Daoud N. Neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Psychopharmacology 2000; 149: 327–44PubMedGoogle Scholar
  52. 52.
    Chick J, Howlett H, Morgan MY, et al. United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol 2000; 35: 176–87PubMedGoogle Scholar
  53. 53.
    Lhuintre JP, Moore ND, Tran G, et al. Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol Alcohol 1990; 25: 613–22PubMedGoogle Scholar
  54. 54.
    Paille FM, Guelfi JD, Perkins AC, et al. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol 1995; 30: 239–47PubMedGoogle Scholar
  55. 55.
    Whitworth AB, Fischer F, Lesch OM, et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 1996; 347: 1438–42PubMedGoogle Scholar
  56. 56.
    Tempesta E, Janiri L, Bignamini A, et al. Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol 2000; 35: 202–9PubMedGoogle Scholar
  57. 57.
    Barrias JA, Chabac S, Ferreira L, et al. Acamprosate: multicenter Portuguese efficacy and tolerance evaluation study. Psiquiatria Clinica 1997; 18: 149–60Google Scholar
  58. 58.
    Gual A, Lehert P. Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain. Alcohol Alcohol 2001; 36: 413–8PubMedGoogle Scholar
  59. 59.
    Sass H, Soyka M, Mann K, et al. Relapse prevention by acamprosate: results from a placebo controlled study in alcohol dependence. Arch Gen Psychiatry 1996; 53: 673–80PubMedGoogle Scholar
  60. 60.
    Geerlings PJ, Ansoms C, Van Der Brink W. Acamprosate and prevention of relapse in alcoholics. Eur Addict Res 1997; 3: 129–37Google Scholar
  61. 61.
    Poldrugo F. Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction 1997; 92: 1537–46PubMedGoogle Scholar
  62. 62.
    Pelc I, Verbanck P, Le Bon O, et al. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. Br J Psychiatry 1997; 170: 73–7Google Scholar
  63. 63.
    Namkoong K, Lee BO, Lee PG, et al. Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study. Alcohol Alcohol 2003; 38: 135–41PubMedGoogle Scholar
  64. 64.
    Roussaux JP, Hers D, Ferauge M. Does acamprosate diminish the appetite for alcohol in weaned alcoholics. J Pharm Belg 1996; 51: 65–8PubMedGoogle Scholar
  65. 65.
    Besson J, Aeby F, Kasas A, et al. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res 1998; 22: 573–9PubMedGoogle Scholar
  66. 66.
    Pelc I, Le Bon O, Verbanck P, et al. Calcium acetyl homotaurinate for maintaining abstinence in weaned alcoholic patients; a placebo controlled double-blind multi-centre study. In: Naranjo C, Sellers E, editors. Novel pharmacological interventions for alcoholism. New York, USA: Springer Verlag, 1992: 348–52Google Scholar
  67. 67.
    Lhuintre JP, Daoust M, Moore ND, et al. Ability of calcium acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics. Lancet 1985; I: 1014–6Google Scholar
  68. 68.
    Ladewig D, Knecht T, Lehert P, et al. Acamprosate: a stabilising factor in long-term withdrawal of alcoholic patients. Ther Umsch 1993; 50: 182–8PubMedGoogle Scholar
  69. 69.
    Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in maintaining abstinence in alcohol-dependent individuals: results of a meta-analysis. J Stud Alcohol 2004 Jan; 65(1): 136–9Google Scholar
  70. 70.
    Rubio G, Jiménez-Arriero MA, Ponce G, et al. Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment. Alcohol Alcohol 2001; 36: 419–25PubMedGoogle Scholar
  71. 71.
    Gerra G, Caccavari R, Delsignore R, et al. Effects of fluoxetine and Ca-acetyl-homotaurinate on alcohol intake in familial and non-familial alcoholic patients. Curr Ther Res 1992; 52: 291–5Google Scholar
  72. 72.
    Pelc I, Ansoms C, Lehert P, et al. The European NEAT program: an integrated approach using acamprosate and psychosocial support for the prevention of relapse in alcohol-dependent patients with a statistical modelling of therapy success prediction. Alcohol Clin Exp Res 2002; 26: 1529–38PubMedGoogle Scholar
  73. 73.
    De Wildt WAJM, Schippers GM, Van den Brink W, et al. Does psychosocial treatment enhance the efficacy of acamprosate in patients with alcohol problems? Alcohol Alcohol 2002; 4: 375–82Google Scholar
  74. 74.
    Mason BJ, Ritvo EC, Morgan RO, et al. A double-blind placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin Exp Res 1994; 18: 1162–7PubMedGoogle Scholar
  75. 75.
    Mason BJ, Salvato FR, Williams LD, et al. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry 1999; 56: 719–24PubMedGoogle Scholar
  76. 76.
    Mäkelä R, Kallio A, Karhuvaara S, et al. Nalmefene in the treatment of heavy drinkers [abstract]. International Society of Addiction Medicine (ISAM) 2001 Sep 12–14: Trieste 2001Google Scholar
  77. 77.
    Noble EP. Alcoholism and the dopaminergic system: a review. Addict Biol 1996; 1: 333–48PubMedGoogle Scholar
  78. 78.
    Peters DH, Faulds D. Tiapride: a review of its pharmacology and therapeutic potential in the management of alcohol dependence syndrome. Drugs 1994; 47: 1010–32PubMedGoogle Scholar
  79. 79.
    Shaw GK, Waller S, Majumdar SK, et al. Tiapride in the prevention of relapse in recently detoxified alcoholics. Br J Psychiatry 1994; 165: 512–23Google Scholar
  80. 80.
    Shaw GK, Majumdar SK, MacGarvie J, et al. Tiapride in the long-term management of alcoholics of anxious or depressive temperament. Br J Psychiatry 1987; 150: 164–8PubMedGoogle Scholar
  81. 81.
    Wiesbeck GA, Weijers JG, Lesch OM, et al. Flupenthixol decanoate and relapse prevention in alcoholics: results from a placebo-controlled trial. Alcohol Alcohol 2001; 36: 329–34PubMedGoogle Scholar
  82. 82.
    Marra D, Warot D, Berlin I, et al. Amisulpride does not prevent relapse in primary alcohol dependence: results of a pilot randomized, placebo-controlled trial. Alcohol Clin Exp Res 2002; 26: 1545–52PubMedGoogle Scholar
  83. 83.
    Linnoila M, Eckardt M, Durcan M, et al. Interactions of serotonin with ethanol: clinical and animal studies. Psychopharmacol Bull 1987; 23: 452–7PubMedGoogle Scholar
  84. 84.
    McGrath PJ, Nunes EV, Stewart JW, et al. Imipramine treatment of alcoholics with major depression. Arch Gen Psychiatry 1996; 53: 232–40PubMedGoogle Scholar
  85. 85.
    Mason BJ, Kocsis JH, Ritvo EC, et al. A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. JAMA 1996; 275: 761–7PubMedGoogle Scholar
  86. 86.
    Gorelick DA, Paredes A. Effects of fluoxetine on alcohol consumption in male alcoholics. Alcohol Clin Exp Res 1992; 16: 261–5PubMedGoogle Scholar
  87. 87.
    Kranzler HR, Burleson JA, Korner P, et al. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry 1995; 152: 391–7PubMedGoogle Scholar
  88. 88.
    Janiri L, Gobbi G, Manneli P, et al. Effects of fluoxetine at antidepressant doses on short-term outcome of detoxified alcoholics. Int Clin Psychopharmacol 1996; 11: 109–17PubMedGoogle Scholar
  89. 89.
    Kabel DI, Petty F. A placebo-controlled, double-blind study of fluoxetine in severe alcohol-dependence: adjunctive pharmacotherapy during and after inpatient treatment. Alcohol Clin Exp Res 1996; 20: 780–4PubMedGoogle Scholar
  90. 90.
    Cornelius JR, Salloum IM, Ehler JG, et al. Fluoxetine in depressed alcoholics: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997; 54: 700–5PubMedGoogle Scholar
  91. 91.
    Roy A. Placebo-controlled study of sertraline in depressed recently abstinent alcoholics. Biol Psychiatry 1998; 44: 633–7PubMedGoogle Scholar
  92. 92.
    Pettinati HM, Volpicelli JR, Luck G, et al. Double-blind clinical trial of sertraline treatment for alcohol dependence. J Clin Psychopharmacol 2001; 21: 143–53PubMedGoogle Scholar
  93. 93.
    CoŞkunol H, Gökden O, Sabri Ercan E, et al. Long-term efficacy of sertraline in the prevention of alcoholic relapses in alcohol-dependent patients: a single-center, double-blind, randomized, placebo-controlled, parallel-group study. Curr Ther Res 2002; 63: 759–71Google Scholar
  94. 94.
    Gual A, Balcells M, Torres M, et al. Sertraline for the prevention of relapse in detoxicated alcohol dependent patients with a comorbid depressive disorder: a randomized controlled trial. Alcohol Alcohol 2003; 38: 619–25PubMedGoogle Scholar
  95. 95.
    Naranjo CA, Bremner KE, Lanctot KA. Effects of citalopram and a brief psychosocial intervention on alcohol intake, dependence and problems. Addiction 1995; 90: 87–99PubMedGoogle Scholar
  96. 96.
    Tiihonen J, Ryynanen DP, Kauhanen J, et al. Citalopram in the treatment of alcoholism. Pharmacopsychiatry 1996; 29: 27–9PubMedGoogle Scholar
  97. 97.
    Johnson BA, Jasinski DR, Galloway GP, et al. Ritanserin in the treatment of alcohol dependence: a multi-center clinical trial. Ritanserin Study Group. Psychopharmacology 1996; 128: 206–15Google Scholar
  98. 98.
    Wiesbeck GA, Weijers JG, Chick J, et al. Ritanserin in relapse prevention in abstinent alcoholics: results from a placebo-controlled, double-blind international multicenter trial. Ritanserin in Alcoholism Work Group. Alcohol Clin Exp Res 1999; 23: 230–5PubMedGoogle Scholar
  99. 99.
    Sellers EM, Toneatto T, Romach MK, et al. Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol Clin Exp Res 1994; 18: 879–85PubMedGoogle Scholar
  100. 100.
    Johnson BA, Roace JD, Javors MA, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomised clinical trial. JAMA 2000; 284: 1016–7Google Scholar
  101. 101.
    Bruno F. Buspirone in the treatment of alcoholic patients. Psychopathology 1989; 22: 49–59PubMedGoogle Scholar
  102. 102.
    Tollefson GD, Montague-Clouse J, Tollefson SL. Treatment of comorbid generalized anxiety in a recently detoxified alcoholic population with a selective serotonergic drug (buspirone). J Clin Psychopharmacol 1992; 12: 19–26PubMedGoogle Scholar
  103. 103.
    Malcolm R, Anton RF, Randall CL, et al. A placebo-controlled trial of buspirone in anxious inpatient alcoholics. Alcohol Clin Exp Res 1992; 16: 1007–13PubMedGoogle Scholar
  104. 104.
    Kranzler HR, Burleson JA, Del Boca FK, et al. Buspirone treatment of anxious alcoholics: a placebo-controlled trial. Arch Gen Psychiatry 1994; 51: 720–31PubMedGoogle Scholar
  105. 105.
    Malec TS, Malec EA, Dongier M. Efficacy of buspirone in alcohol dependence: a review. Alcohol Clin Exp Res 1996; 20: 853–8PubMedGoogle Scholar
  106. 106.
    Malec TS, Malec EA, Gagne MA, et al. Efficacy of buspirone in alcohol dependence: a placebo-controlled trial. Alcohol Clin Exp Res 1996; 20: 309–12Google Scholar
  107. 107.
    Messiha FS, Butler D, Adams MK. Carbamazepine and ethanol elicited responses in rodents. Alcohol 1986; 3: 131–3PubMedGoogle Scholar
  108. 108.
    Alexander GJ, Alexander RB. Alcohol comsumption in rats treated with lithium carbonate or rubidium chloride. Pharmacol Biochem Behav 1978; 8: 533–6PubMedGoogle Scholar
  109. 109.
    Doras W, Ostrow DG, Anton R, et al. Lithium treatment of depressed and nondepressed alcoholics. JAMA 1989; 262: 1646–52Google Scholar
  110. 110.
    Mueller TI, Stout RL, Rudden S, et al. A double-blind placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. Alcohol Clin Exp Res 1997; 21: 86–91PubMedGoogle Scholar
  111. 111.
    Gallimberti L, Ferri M, Ferrara SD, et al. Gamma-hydroxybutyric acid in the treatment of alcohol dependence: a double-blind study. Alcohol Clin Exp Res 1992; 16: 673–6PubMedGoogle Scholar
  112. 112.
    Ait-Daoud N, Johnson BA, Prihoda TJ, et al. Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: preliminary clinical evidence. Psychopharmacology 2001; 154: 23–7PubMedGoogle Scholar
  113. 113.
    Wilde MI, Wagstaff AJ. Acamprosate: a review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drags 1997; 53: 1038–53Google Scholar
  114. 114.
    Croop RS, Faulkner EB, Labriola DF. The safety profile of naltrexone in the treatment of alcoholism. Arch Gen Psychiatry 1997; 54: 1130–5PubMedGoogle Scholar
  115. 115.
    Chick J. Safety issues concerning the use of disulfiram in treating alcohol dependence. Drug Saf 1999; 20: 427–35PubMedGoogle Scholar
  116. 116.
    Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drag abuse: results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264: 2511–8PubMedGoogle Scholar
  117. 117.
    Kessler RC, Cram RM, Warber LA, et al. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry 1997; 54: 313–21PubMedGoogle Scholar
  118. 118.
    Swift RM. Drag therapy for alcohol dependence. N Engl J Med 1999; 340: 1482–7PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  • Karl Mann
    • 1
  1. 1.Department of Addictive Behaviour and Addiction Medicine, Central Institute of Mental HealthUniversity of HeidelbergMannheimGermany

Personalised recommendations